The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr Bugianesi MD, PhD, is currently Professor of Gastroenterology and Scientific Director of the Dept of Medical Sciences at the University of Turin in Italy. Dr Bugianesi received her MD and her Internal Medicine Residency at the University of Bologna. Her post-graduate training included a PhD fellowship at Case Western Reserve University, Cleveland, USA, from 1995 to 1998 where she became expert in the use of stable isotopes to study in vivo metabolism.
Dr Bugianesi is an international acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15-years’ experience. She contributed to the field with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease (including the first demonstration of HCC as a complication of NASH), the development of non-invasive markers of fibrosis, and the involvement in several trials for the treatment of NAFLD/NASH. Her contribution to science is testified by over 200 publications, an H Index = 66, N. Citations = 20730 (Scopus).
She has been national PI of major EU funded research consortia: Fatty Liver: Inhibition of Progression (FLIP) (2010-2013), ‘EPoS’ Elucidating Pathways of Steatohepatitis (2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (IMI2, 2017-2022). As clinician, she is a practicing Hepatologist based at the GI Division of the University Hospital “Città della Salute e della Scienza of Torino”, Italy.